Have a feature idea you'd love to see implemented?
Let us know!
VSTM Verastem Inc
Price (delayed)
$3.93
Market cap
$174.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.2
Enterprise value
$103.17M
Verastem Oncology is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. The company's pipeline is focused on
Highlights
Verastem's EPS has increased by 21% YoY and by 4.5% QoQ
Verastem's equity has shrunk by 87% YoY and by 41% QoQ
Verastem's quick ratio has plunged by 57% YoY and by 2.6% from the previous quarter
Key stats
What are the main financial stats of VSTM
Market
Valuations
Earnings
Shares outstanding
44.51M
Market cap
$174.91M
Enterprise value
$103.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
14.3
Price to sales (P/S)
15.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.32
Revenue
$10M
EBIT
-$88.92M
EBITDA
-$89.09M
Free cash flow
-$109.38M
Per share
Balance sheet
Liquidity
EPS
-$3.2
Free cash flow per share
-$2.72
Book value per share
$0.27
Revenue per share
$0.25
TBVPS
$3.14
Total assets
$126.38M
Total liabilities
$94.16M
Debt
$41.43M
Equity
$11.06M
Working capital
$83.29M
Debt to equity
3.75
Current ratio
3.23
Quick ratio
3.03
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-890.9%
Gross margin
100%
Net margin
-934.5%
Operating margin
-1,146.4%
Return on assets
-74%
Return on equity
-332.7%
Return on invested capital
-182.2%
Return on capital employed
-99.9%
Return on sales
-889.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VSTM stock price
How has the Verastem stock price performed over time
Intraday
3.69%
1 week
-4.84%
1 month
10.08%
1 year
-37.42%
YTD
-51.72%
QTD
31.44%
Financial performance
How have Verastem's revenue and profit performed over time
Revenue
$10M
Gross profit
$10M
Operating income
-$114.64M
Net income
-$93.45M
Gross margin
100%
Net margin
-934.5%
The company's operating income fell by 47% YoY and by 16% QoQ
VSTM's net income is down by 22% year-on-year and by 4.4% since the previous quarter
Verastem's operating margin has decreased by 16% from the previous quarter
Verastem's net margin has decreased by 4.4% from the previous quarter
Growth
What is Verastem's growth rate over time
Valuation
What is Verastem stock price valuation
P/E
N/A
P/B
14.3
P/S
15.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.32
Verastem's EPS has increased by 21% YoY and by 4.5% QoQ
The stock's P/B is 88% above its last 4 quarters average of 7.6
Verastem's equity has shrunk by 87% YoY and by 41% QoQ
Efficiency
How efficient is Verastem business performance
Verastem's return on equity has shrunk by 187% YoY and by 71% QoQ
The ROIC has contracted by 48% from the previous quarter and by 24% YoY
The ROA has contracted by 41% YoY and by 15% from the previous quarter
Verastem's return on sales has decreased by 4.6% QoQ
Dividends
What is VSTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VSTM.
Financial health
How did Verastem financials performed over time
The total assets is 34% greater than the total liabilities
Verastem's quick ratio has plunged by 57% YoY and by 2.6% from the previous quarter
The company's current ratio has shrunk by 56% YoY
Verastem's equity has shrunk by 87% YoY and by 41% QoQ
VSTM's debt to equity has surged by 69% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.